| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The Ras-Raf-MEK-ERK signaling pathway plays pivotal roles in cell proliferation and cell growth and mutations in Ras or Raf have been frequently identified from various tumor cells. MEK inhibitors are effective in suppressing cell growth of Raf-mutant cells but not in Ras-mutant cells. To reveal working principles of the MEK inhibitor resistance in cancer cells, in this study, we constructed a system for controlling and monitoring mTORC1 activity, which is a downstream signaling of Ras. In addition, we established stable cell lines for analyzing dynamics of cell cycle progression of living tumor cells under perturbations of ERK or mTORC1 signaling. Combination of these approaches would be expected to identify the principles of cell growth control and that of MEK inhibitor resistance.
|
